Abstract:Objective An ELISA-based assay for detecting alloantibodies against FⅧ was established to estimate the incidence of alloantibodies against FⅧ in treated patients with hemophilia A. Methods One hundred and forty patients with hemophilia A and 80 healthy controls were enrolled. Among hemophilia A patients, 84, 34 and 22 patients were in severe, moderate and mild conditions respectively. All patients were treated with plasma-derived FⅧ concentrates before. The titer wells were coated with MoAb against FⅧ which was developed in our laboratory. Then human recombinant FⅧ concentrates were applied. After incubation in room temperature for 2 hours, diluted plasma samples and HRP-conjugated goat anti-human IgG were added successively. Finally Absorbance (A490) were measured and recorded. Inhibitor activity against FⅧ for all plasma samples was measured by a modified Nijmegen assay simultaneously. Results The results showed that alloantibodies against FⅧ were found in 40.0% (56/140) patients by ELISA. And the alloantibody incidences in the severe and non-severe patients were 47.6% (40/84) and 28.5% (16/56)respectively. There was statistical significance between these two categories (x2 = 5.079, P ＜ 0.05 ). The FⅧ inhibitor activity was detected in 24.3% (34/140) patients by modified Nijmegen assay. The inhibitor incidences in the severe and non-severe patients were 33.3% (28/84) and 10.7% (6/56) respectively.There was statistical significance (x2 = 9.349, P ＜ 0.05). Twenty-five patients were positive for FⅧ alloantibodies by ELISA but had no FⅧ inhibitor activity by the modified Nijmegen assay. The positive rates of FⅧ alloantibodies and inhibitor activity were 40.0% (56/140) and 24.3% (34/140) respectively,which had significant difference (x2 = 15.75, P ＜ 0.01 ) and strong positive correlation ( rn = 0.59, P ＜0.01 ). Meanwhile the results deduced from these two tests shared a high consistency rate ( Kappa = 0.55,P ＜0.01 ). Conclusions The detection rate for alloantibodies against F Ⅷ is enhanced by our newlydeveloped ELISA. Our results suggest that the occurrence of the alloantibodies against F Ⅷ in Chinese hemophilia A patients is not rare and the alloantibody incidence is preponderant in the patients with severe hemophilia A compared with non-severe hemophilia A patients.

[Detection of Alloantibodies Against Factor VIII in Plasma of Patients with Hemophilia A and Its Relationship with Factor VIIIC Domain].

Measurement of Alloantibodies Against FⅧ in Patients with Hemophilia A Using a Newly-Developed ELISA and Its Clinical Application

[Association of Coagulation Factor V, VII Gene Polymorphisms with Coronary Heart Disease].

[Molecular Analysis of a Patient with Hemophilia A Caused by FVIII His99Arg Mutation].

Assay of factor VIII antigen (VIII:CAg) in 294 haemophilia A patients by a new commercial ELISA using monoclonal antibodies

Association of FVIII Val34Ldu with Coronary Heart Disease

Detection by Denaturing Gradient Gel Electrophoresis of an Arg1689Cys Mutation in a Chinese Patient with Mild Hemophilia A.

Application of von Willebrand Factor Antigen test in the Differential Diagnosis of von Willebrand Disease and Hemophilia A

Prevalence of the Factor 8 Gene Intron 1 Inversion in Chinese Haemophiliacs and Its Application to Carrier Detection and Prenatal Diagnosis in Haemophilia A Families

Clinical application evaluation of chromogenic substrate assay in detecting coagulation factor Ⅷ activity

Mutation Detection and Inhibitor Analysis of 43 Children with Severe Hemophilia A in a Single Center: Three Novel Mutations

Detection of Serum Anti-F in Hepatitis C Virus Infected Patients

FVIII peptides presented on HLA-DP and identification of an A3 domain peptide binding with high affinity to the commonly expressed HLA-DP4

[Analysis of Coagulation Factor VIII Inhibitor Development Related Factors in Hemophilia A Patients.].

[Detection of Serum Anti-F Antibody in Hepatitis C Virus Infected Patients].

[Relationship Between Factor VIII Inhibitor Development and Polymorphisms of TNFα and CTLA-4 Gene in Chinese Han Patients with Hemophilia A].

Phenotypes of Allo- and Autoimmune Antibody Responses to FVIII Characterized by Surface Plasmon Resonance

Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A

A Strategy for the Molecular Diagnosis in Hemophilia A in Chinese Population

Factor VIII Antigen, Activity, and Mutations in Hemophilia A

[Development of a Monoclonal Antibody to Factor VIII C2 Domain and Its Functional Study].